Baxdrostat Approved for Uncontrolled Hypertension

In May 2026, the U.S. Food and Drug Administration approved baxdrostat (Baxfendy) as an add-on therapy for patients who have uncontrolled hypertension despite treatment with other antihypertensive agents. This drug directly inhibits the synthesis of aldosterone, whereas the other available agents inhibiting the effect of aldosterone (e.g., spironolactone and eplerenone) block its receptor. Baxdrostat is the third recently approved treatment for this population, alongside aprocitentan and renal denervation.